Jump to content

Mefenorex

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 00:51, 8 May 2017. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Mefenorex
Clinical data
ATC code
Legal status
Legal status
Identifiers
  • 3-chloro-N-(1-methyl-2-phenylethyl)propan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.037.511 Edit this at Wikidata
Chemical and physical data
FormulaC12H18ClN
Molar mass211.731 g·mol−1
3D model (JSmol)
  • ClCCCNC(Cc1ccccc1)C
  • InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3 checkY
  • Key:XXVROGAVTTXONC-UHFFFAOYSA-N checkY
  (verify)

Mefenorex (Rondimen, Pondinil, Anexate) is a stimulant drug which was used as an appetite suppressant. It is an amphetamine derivative which was developed in the 1970s and used for the treatment of obesity.[1][2] Mefenorex produces amphetamine as a metabolite,[3] and has been withdrawn in many countries despite having only mild stimulant effects and relatively little abuse potential.[4]

References

  1. ^ Vincendeau MJ. A new regulator of appetite: mefenorex. (French). Bordeaux Medical. 1970 Jul-Aug;3(7):1951-3.
  2. ^ Beyer G, Huth K, Muller GM, Niemoller H, Raisp I, Vorberg G. The treatment of obesity with the appetite curbing agent Mefenorex. (German). Die Medizinische Welt. 1980 Feb;31(8):306-9.
  3. ^ Rendic S, Slavica M, Medic-Saric M. Urinary excretion and metabolism of orally administered mefenorex. European Journal of Drug Metabolism and Pharmacokinetics. 1994 Apr-Jun;19(2):107-17.
  4. ^ Engel J, Kristen G, Schaefer A, von Schlichtegroll A. Mefenorex (Rondimen). Drug and Alcohol Dependence. 1986 Jun;17(2-3):229-34.